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human pharmacology of current and novel  
gaba-a-ergic treatments for anxiety
1 The pharmacological selectivity of novel α2,3-subtype selective gaba(a) 
receptor partial agonists is demonstrated by their distinct effect profile on 
the neurophysiological and neuropsychological measurements reflecting the 
function of multiple cns-domains, in comparison with benzodiazepines, the 
non-selective full gaba(a) agonists (this thesis).  
2 Normalizing the off-target pharmacodynamic effects against the on-target 
effect on saccadic peak velocity is a useful approach to present the 
pharmacological feature of gaba(a)ergic modulators (this thesis). 
3 Combination of anxiogenic symptom provocation paradigm with the validated 
neurophysiological and neuropsychological biomarkers may provide further 
construct validity for clinical effects of novel anxiolytic agents (this thesis).  
4 There is considerable preclinical evidence that the gabaergic system in general 
and its α2,3 subunit-containing gaba(a) receptor subtypes in particular 
are implicated in the pathophysiology of anxiety disorders. Nonetheless, 
the clinical efficacy of selective gaba-a-α2,3-agonists for anxiety disorders 
has not been unequivocally demonstrated. This could be related to the 
underestimation of pharmacologically active doses in early drug development 
(this thesis). 
5 Personalised medicine is an interesting concept that assumes individual 
variability in responsiveness to medicines. However, personalised medicine 
can only be widely applied if there are sensitive and specific and quantitative 
measures of this responsiveness in individuals. These are currently lacking 
in most diseases and clinical pharmacologists are ideally placed to play an 
important role in the development of such measures (Cohen AF, email to Xia Chen, 
Aug 16, 2017). 
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6 In the roadmap of novel drug discovery and development, translational 
medicine seeks to translate biological and molecular knowledge of disease  
and pharmacological features of a drug into innovative strategies that reduce 
the cost and increase the speed of delivering new medicines for patients 
(adapted from: Bruce Littman & Rajesh Krishma, Translation Medicine and Drug 
Discovery, 2011; Preface:1). 
7 The essence of rational drug development is to ask important questions  
and answer them with appropriate studies using fit-for-purpose biomarkers  
(Cohen AF et al., Annu Rev Pharmcol Toxicol 2015; 55: 55-74). 
8 Anxiety disorders arise from disruption of the highly interconnected 
circuits normally serving to process the stream of potentially threatening 
stimuli. The resultant imbalance in these circuits cause a fundamental 
misinterpretation of neural sensory information as threatening and leads 
to the inappropriate emotional- and thereby behavioral-responses seen 
in anxiety disorders (adapted from: Calhoon GG & Tye KM. Nat Neurosci. 2015; 
18(10): 1394-404.). 
9 Whereof one cannot speak, thereof one must be silent. We should recognize 
how little is achieved when a specific research problem is solved. (adapted from 
Ludwig Wittgenstein, Tractatus Logico-Philosophicus, 1922)
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